USPSTF Stance on BRCA Genetic Screening
The USPSTF recommends that primary care providers screen women with a family history of breast, ovarian, tubal, or peritoneal cancer using validated risk assessment tools, and refer those who screen positive for genetic counseling and, if indicated, BRCA1/2 testing (B recommendation), while recommending against routine screening for women without such family history (D recommendation). 1
Risk-Stratified Approach
The USPSTF takes a two-tiered approach based on family history risk:
For High-Risk Women (B Recommendation)
Primary care providers should actively screen women who have family members with:
- Breast cancer (especially diagnosed before age 50)
- Ovarian, tubal, or peritoneal cancer
- Bilateral breast cancer
- Male family members with breast cancer
- Multiple cases of breast cancer in the family
- Ashkenazi Jewish ancestry
These women should receive genetic counseling and, if indicated after counseling, proceed to BRCA testing. 1
For Average-Risk Women (D Recommendation)
The USPSTF explicitly recommends against routine genetic counseling or BRCA testing for women whose family history does not suggest increased risk for BRCA mutations. 1
Validated Screening Tools
The USPSTF evaluated several brief familial risk assessment tools for primary care use, including:
- Family History Screen-7 (FHS-7) - simplest and quickest
- Referral Screening Tool (B-RST) - simplest and quickest
- Ontario Family History Assessment Tool
- Manchester Scoring System
- Pedigree Assessment Tool
All demonstrate sensitivity >85% for identifying women who should be referred for genetic counseling. 1 The USPSTF found insufficient evidence to recommend one tool over another, but emphasizes that general breast cancer risk models like the Gail model should NOT be used for determining who needs BRCA assessment, as they are not designed for this purpose. 1
Critical Implementation Details
Who Should Be Tested First
When possible, testing should begin with an affected family member (someone who has had breast or ovarian cancer) rather than an unaffected individual. However, testing an unaffected woman is reasonable if no affected relative is available for testing. 1
Genetic Counseling Requirements
BRCA testing should only occur when:
- The individual has personal or family history suggesting inherited cancer susceptibility
- Access to trained genetic counseling is available
- Test results will aid in decision-making
- The individual is fully informed and desires testing 1
Test Result Interpretation Complexity
Results require posttest counseling and fall into categories:
- Positive: Potentially harmful mutation detected
- True-negative: No mutation in families with known mutations (reassuring)
- Uninformative-negative: No mutation detected but no relatives tested or no mutations found in tested relatives (breast cancer risk remains elevated) 1
- Variants of uncertain significance: Unclear clinical meaning
Updated 2019 Guidance
The USPSTF reaffirmed this approach in 2019, expanding to include women with ancestry associated with BRCA1/2 mutations (particularly Ashkenazi Jewish heritage) as another indication for risk assessment, even without specific family history. 2
Common Pitfalls
Implementation Gap
Despite clear guidelines since 2005, real-world implementation remains poor. Research shows only 22% of high-risk women are actually referred for testing, with Black patients significantly less likely to be referred than white patients, and most primary care physicians never referring a single patient over a decade. 3 Among screen-positive women, only 9.5% report discussing genetic testing with their provider. 4
Wrong Risk Tool Usage
Do not use the Gail model or other general breast cancer risk assessment tools to determine who needs BRCA evaluation—these are not designed for hereditary risk assessment. 1
Timing Considerations
Screening should begin once women reach age 18, with periodic reassessment for changes in family history throughout their lives. 1
Rationale for Recommendations
For women with increased familial risk, the benefits of risk assessment, genetic counseling, testing, and subsequent interventions (intensive screening, risk-reducing medications, or surgery) are moderate, while harms are small to moderate. For women without increased risk, benefits are small to none, making routine screening inappropriate. 2